A Study of Changes to Prostate Procedures
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 20, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of using local anesthesia during a specific type of prostate biopsy, known as a transperineal biopsy, while patients are also given sedation through an IV (a small tube placed in a vein). The main goal is to see if the local anesthesia helps reduce the pain that patients feel in the recovery room after the procedure. Researchers will also measure how much pain medication is used, how quickly patients can go home, and how well they recover after leaving the hospital.
Men between the ages of 65 and 74 who are scheduled for a transperineal prostate biopsy at the JRSC may be eligible to participate in this study. Participants can expect to receive either local anesthesia or not during their biopsy and will be monitored for their pain levels and recovery. This study is currently recruiting volunteers, and there are no specific health issues that would exclude someone from participating. If you're interested in the study, it's a good opportunity to help improve prostate cancer procedures for future patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- Local anesthesia versus no local anesthesia during transperineal biopsy, while the patient is under IV sedation:
- • Patients scheduled for transperineal prostate biopsy at the JRSC or Monmouth.
- Standardization of a periprocedural pathway versus usual care for focal gland ablation:
- • Patients scheduled for a partial prostate gland ablation procedure at the JRSC.
- Exclusion Criteria:
- Local anesthesia versus no local anesthesia during transperineal biopsy, while patient is under IV sedation:
- • None
- Standardization of a periprocedural pathway versus usual care for focal gland ablation:
- • None
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jonathan Fainberg, MD, MPH
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported